Hormel Foods Corp Dossier
|
SectorConsumer Staples IndustryPackaged Foods Beta (adjusted)0.56 Intrinsic Value $22.28median of 6 methods · middle span $13-$30based on filings through 26 Jul 2026 Market Price $19.96Price as of 1 Oct 2026 Near fair valueIntrinsic value is 12% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $11B Enterprise Value $13B Shares Outstanding 551M diluted Moat Rating None Next Earnings Date3 Dec 2026 Last ex-dividend13 Jul 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Hormel Foods is demonstrating solid execution on its 'Transform & Modernize' initiative, delivering its sixth consecutive quarter of organic top-line growth in Q2 2026. The company's strategic divestiture of the volatile whole-bird turkey business highlights a deliberate shift toward higher-margin, value-added protein products. However, near-term headwinds including commodity cost volatility, elevated fuel and logistics expenses, and planned inventory rebalancing are expected to pressure Q3 2026 margins, keeping third-quarter adjusted earnings flat year-over-year. While the stock's 4.8% dividend yield provides a reliable income floor, current valuation multiples reflect a fair pricing of its slow-growth profile, justifying a Hold rating. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$25.00 Mean target$27.00 High · most bullish analyst$30.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario Persistent commodity cost inflation and high logistics expenses continue to erode gross margins. The planned inventory rebalancing leads to prolonged underutilization of manufacturing plants, and volume contraction in the retail segment accelerates as consumers trade down to private-label alternatives. The 'Transform & Modernize' program fails to offset these headwinds, causing adjusted EPS to miss the full-year guidance range. Base CaseCentral scenario The company successfully navigates near-term cost pressures and inventory rebalancing in Q3 2026. Full-year fiscal 2026 organic net sales grow between 1% and 4%, and adjusted diluted EPS lands in the upper half of the guided $1.43 to $1.51 range. Margins gradually recover as the 'Transform & Modernize' program delivers targeted savings, and the stock trades in line with its historical forward P/E multiple of 14-15x. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |